Restoring immune tolerance, precisely
Anokion (anokion.com) scores 51 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 2nd percentile of 17546 Healthcare brands.
Anokion is a biotechnology company developing antigen-specific immune tolerance therapies for autoimmune and antigen-mediated diseases, such as celiac disease. Using a proprietary platform that employs engineered antigens, the company aims to restore immune tolerance precisely, avoiding the broad immunosuppression associated with conventional treatments. Anokion's work targets patients with autoimmune conditions, as well as clinicians, researchers, and pharmaceutical partners interested in novel tolerance-inducing therapeutics. The company positions itself as an innovator in this emerging therapeutic category, with potential applications across multiple autoimmune indications.
| Brand Name | Anokion |
|---|---|
| Domain | anokion.com |
| Industry | Healthcare |
| Main Competitors | Selecta Biosciences, COUR Pharmaceuticals (74/100), Parvus Therapeutics (75/100), Pandion Therapeutics (45/100), Provention Bio (76/100) |
Moz Domain Authority 33/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Anokion Mobile Menu Toggle navigation" (Meta description: 5 words. OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on X (Twitter), Instagram; no detected presence on LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Anokion?", Claude could identify the brand as of October 2026. Anokion is a biotechnology company developing antigen-specific immunotherapies for autoimmune diseases, using a liver-targeting technology platform to induce immune tolerance rather than suppressing the immune system broadly. Best known for Developing tolerance-inducing therapies for autoimmune conditions like celiac disease and multiple sclerosis using liver-targeted antigen delivery.
When asked "Best brands similar to Anokion?", Claude would recommend Anokion as of October 2026. It's a notable clinical-stage biotech with a differentiated approach to autoimmune disease treatment, worth mentioning alongside other immune tolerance companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Anokion's main competitors in Healthcare: COUR Pharmaceuticals (74/100), Parvus Therapeutics (75/100), Pandion Therapeutics (45/100), Provention Bio (76/100).
Sources: Brand Analyzer scan
Anokion has low AI-search visibility, scoring 13/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 22, recommendation 27). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Anokion official site
Anokion scores 27/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Anokion official site
Anokion offers antigen-specific immune tolerance therapies built on a proprietary platform that uses engineered antigens. These therapies are being developed to treat autoimmune and antigen-mediated diseases, including celiac disease, by targeting the immune response precisely rather than suppressing it broadly.
Sources: Anokion official site
Anokion is a biotechnology company focused on developing antigen-specific immune tolerance therapies for autoimmune and antigen-mediated diseases. It uses a proprietary platform built around engineered antigens to create treatments intended to restore immune tolerance without relying on broad immunosuppression.
Sources: Anokion official site
Anokion develops antigen-specific therapies designed to restore immune tolerance in patients with autoimmune diseases, such as celiac disease. Its proprietary platform uses engineered antigens to deliver precise, targeted treatment, aiming to avoid the side effects associated with traditional broad immunosuppressive therapies.
Sources: Anokion official site
Anokion can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Anokion official site
Anokion's therapies are intended for patients with autoimmune diseases such as celiac disease. The company also engages clinicians, researchers, and pharmaceutical partners who are interested in novel immune tolerance therapies for autoimmune and antigen-mediated conditions.
Sources: Anokion official site
Anokion is known for pioneering antigen-specific immune tolerance therapy as an alternative to broad immunosuppression in treating autoimmune diseases. Its proprietary platform using engineered antigens is positioned as having potential application across multiple autoimmune and antigen-mediated conditions, including celiac disease.
Sources: Anokion official site
Anokion scores 13/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Anokion has a weak AI-visibility profile at 13/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (27/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 33/100. In a live check, Claude could already identify Anokion from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Anokion: American Nutrition Association (51/100), Walgreens Specialty Pharmacy and Walgreens Mail Service (51/100), Asahi Kasei (51/100), Astra Life (51/100).
A step up - brands to learn from: Word of Mouth Technology (56/100), Werskincare (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.